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ABSTRACT 30 
The presence of residues of antibiotics, metabolites and thermal transformation products 31 
(TPs), produced during thermal treatment to eliminate pathogenic microorganisms in milk, 32 
could be represent a risk for people. 33 
 34 
Cow milk samples spiked with enrofloxacin (ENR), ciprofloxacin (CIP), difloxacin (DIF) 35 
and sarafloxacin (SAR) and milk samples from cows medicated with ENR were submitted 36 
to several thermal treatments. The milk samples were analysed by liquid chromatography 37 
mass spectrometry (LC-MS) to find and identify TPs and metabolites. In this work, 27 TPs 38 
of four quinolones and 24 metabolites of ENR were found. Some of these compounds had 39 
been reported previously, but others were characterized for the first time, including lactose-40 
conjugated CIP, the formamidation reaction for CIP and SAR, and hydroxylation or ketone 41 
formation to produce three different isomers for all quinolones studied. 42 
 43 
 44 
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1. INTRODUCTION 49 
Quinolones are one of the classes of antibiotics that are most widely used in veterinary 50 
practice to treat bacterial infections of animals in livestock farming and bovine milk 51 
production. Antibiotics are also used as growth promoters, although this practice has been 52 
forbidden by the European Union (EU) since 20061. 53 
The presence of antibiotic residues in food is a potential risk to consumers because of 54 
direct toxic effects such as allergic reactions or the induction of resistant strains of 55 
bacteria2,3. To ensure human health, the EU has established maximum residue limits 56 
(MRL) for some antibiotics in foodstuffs of animal origin (37/2010/EC)4. Active 57 
substances are usually included in this regulation. However, their metabolites such as 58 
ciprofloxacin, the main metabolite of enrofloxacin, are only considered in a few cases. 59 
 60 
Milk is one of the most commonly consumed foods in the world. Drug residues and 61 
metabolites can be found in milk if the time between drug administration and milking is 62 
too short. Before consumption, cow milk has to be subjected to thermal treatment to 63 
eliminate pathogenic microorganisms. Two common thermal processes are pasteurization, 64 
which consists of heating at 60ºC for 30 min or at 72ºC for 15 s, and sterilization, by which 65 
milk is heated at 120ºC for 20 min5,6. During thermal processes, the antibiotic residues and 66 
their metabolites could undergo transformations, depending on the temperature and the 67 
duration of the process.  68 
The study of metabolites and their thermal degradation products is of interest because these 69 
new compounds may be a health risk to consumers and could be more persistent and 70 
harmful than the drug administered7. 71 
Numerous papers have been published on analytical methods to determine target 72 
substances and their main metabolites in several matrices8-21. However, there are few 73 
studies on the identification and determination of metabolites, degradation, and 74 
transformation products (TPs). The analytical methods consist of chromatographic 75 
separation prior to detection with a mass spectrometer. Several strategies are used to 76 
identify non-targets, including accurate mass measurement to determine the elemental 77 
composition and distinguish isobaric molecular ions, multiple mass fragmentations (MSn), 78 
and complementary techniques such as NMR to confirm structure7,22-34. Some metabolites 79 
of quinolones are described in the bibliography25,35-41, but to our knowledge no study has 80 
been carried out on metabolites in milk which has been exposed to thermal treatment. 81 
 82 
The aim of this study was to characterize the metabolites and TPs of four quinolones ENR, 83 
CIP, DIF and SAR (Figure 1) in cow’s milk subjected to thermal treatment. In order to test 84 
the new metabolites and TPs found in spiked milk samples, milk samples from animals 85 
medicated with ENR were submitted to the same thermal treatment. Samples were 86 
analysed by liquid chromatography (LC) coupled to high resolution mass spectrometry 87 
(ToF and LTQ-Orbitrap).  88 
 89 
2. EXPERIMENTAL PROCEDURES 90 
2.1. Chemicals and apparatus  91 
The standards were purchased from several pharmaceutical firms: ENR from Cenavisa 92 
(Reus, Spain), CIP from Ipsen Pharma (Barcelona, Spain), DIF from Abbott (Madrid, 93 
Spain) and SAR from AK Scientific Inc. (CA,USA).  94 
 95 
All reagents were of analytical grade unless indicated. Formic acid (HOCHO), acetic acid 96 
(HOAc), acetonitrile (MeCN), methanol (MeOH), sodium dihydrogenphosphate and 97 
sodium hydroxide (NaOH) were supplied by Merck (Darmstadt, Germany). Water was 98 
ultrapurified by a Milli-Q system (Millipore, MA, USA). 99 
 100 
The quinolone individual stock solutions (ENR, CIP, DIF and SAR) were prepared at a 101 
concentration of 500 µg·mL-1 in 50 mM HOAc aqueous solution. The individual working 102 
solutions that were used to spike the milk samples were prepared by dilution of the 103 
individual stock solution at a concentration of 20 µg·mL-1 in water. 104 
 105 
Sodium dihydrogenphosphate solution 0.1 M adjusted with NaOH 5 M to pH 10 was added 106 
to milk samples prior to the clean-up step. 107 
 108 
The SPE cartridges used in this study were Oasis HLB (3 cm3/60 mg), obtained from 109 
Waters (Milford, MA, USA). 110 
 111 
To simulate the thermal treatment of milk, a laboratory oven (Memmert) was used to warm 112 
the samples. A Rotanta 460RS (Hettich Zentrifuguen, Germany) centrifuge was used to 113 
separate precipitated proteins and fat of supernatant after the extraction. The SPE step was 114 
carried out in a Supelco vacuum manifold with disposable liners for 24 cartridges 115 
(Bellefonte, PA, USA), connected to a Supelco vacuum tank. Evaporation to dryness was 116 
performed in a TurboVap LV (Caliper Life Science, Hopkinton, MA, USA). A Crison 117 
2002 potentiometer (±0.1 mV) (Crison, Barcelona, Spain) with a Crison 5203 combined 118 
pH electrode from Orion Research (Boston, MA, USA) was used to measure the pH of the 119 
phosphate solution and the mobile phase.  120 
2.2. Milk samples 121 
Milk samples used in the work have been supplied by the Laboratori Interprofessional 122 
Lleter de Catalunya (ALLIC), control laboratory of milk in Catalonia. The samples were 123 
analysed previously in ALLIC using a screening method to determine if the milk contained 124 
residues of antibiotics. The milk samples that were negative in antibiotics were used as 125 
blank samples in this work. Four positive samples in ENR were used to study the 126 
metabolites.  127 
 128 
2.3. LC-MS instrumentation and working conditions 129 
2.3.1. LC conditions 130 
Quinolones, their metabolites and degradation products were separated in a Zorbax Eclipse 131 
XDB-C8 column (5 µm, 4.6 × 150 mm) from Agilent Technologies (Santa Clara, CA, 132 
USA), using a pre-column Kromasil C8 (5 µm, 4.6 × 15 mm) supplied by Akady 133 
(Barcelona, Spain) when samples were analysed by LC-ToF. A Pursuit UPS C18 column 134 
(2.4 µm, 2 × 50 mm) from Varian (Harbor City, CA, USA) was used when samples were 135 
injected into the LC-LTQ-Orbitrap. 136 
 137 
For both columns, the mobile phase was composed of an aqueous solution of 0.1% 138 
HOCHO (solvent A) and MeCN with 0.1% HOCHO (solvent B) at a constant flow rate of 139 
1 mL·min-1 and 0.3 mL·min-1, respectively. The injection volume was 20 µL in LC-ToF 140 
and 10 µL in LC-LTQ-Orbitrap. Separations were carried out in a Zorbax Eclipse XDB-C8 141 
column for 11 min under the following gradients: from 0 to 1 min, 15% B; 4 min, 45% B; 142 
7 min, 56% B; 8.5 min, 15% B; and 11 min, 15% B. Separations were carried out in a 143 
Pursuit UPS C18 column under the following conditions: from 0 to 3.5 min, 1% B; 4.5 144 
min, 25% B; 5 min, 50% B; 6.5 min, 50% B; 7.5 min, 25% B; 8.5 min, 10% B; and 11 145 
min, 1% B. 146 
 147 
2.3.2. LC-MS (ToF) 148 
A HP Agilent Technologies 1100 LC system was equipped with an autosampler and 149 
coupled to a 6220 oa-ToF LC/MS mass spectrometer with an electrospray ionisation 150 
source (ESI) (Agilent Technologies, Santa Clara, CA, USA). The system was controlled by 151 
Mass Hunter workstation software (Agilent Technologies, Santa Clara, CA, USA) for the 152 
acquisition and processing of data from the ToF mass spectrometer. 153 
 154 
The optimum parameters of  ToF in positive mode were as follows: capillary voltage 4000 155 
V, drying gas (N2) temperature 300ºC, drying gas (N2) flow rate 9 L·min-1, nebulizer gas 156 
(N2) 40 psi, fragmentor voltage 150 V, skimmer voltage 60 V, and OCT 1 RF voltage 250 157 
V. The ToF-MS mass resolving power was approximately 10,000 FWHM (Full width at 158 
half maximum) at m/z 922. Spectra were acquired over the m/z 50-1100 range. Data 159 
storage was in profile and centroid modes.  160 
 161 
 162 
2.3.3. LC-MS (LTQ-Orbitrap) 163 
An Accela LC system (Thermo Scientific, Hemel Hempstead, UK) was equipped with a 164 
thermostatic autosampler and coupled to an LTQ Orbitrap Velos mass spectrometer 165 
(Thermo Scientific, Hemel Hempstead, UK), with an ESI source. XCalibur software was 166 
used for the data analyses. 167 
 168 
The operation parameters used were source voltage, 3.5 kV; sheath gas (N2): 40 (arbitrary 169 
units); auxiliary gas (N2): 10 (arbitrary units); sweep gas (N2):  10 (arbitrary units); and 170 
capillary temperature, 275°C. Default values were used for most other acquisition 171 
parameters (Fourier transform (FT) automatic gain control (AGC) target 1·106 for MS 172 
mode and 5·104 for MSn mode). Milk samples were first analysed in full MS mode with the 173 
Orbitrap mass resolving power set at 30,000 FWHM at m/z 400. The following analyses 174 
were carried out in MSn mode with the Orbitrap mass resolving power set at 15,000 175 
FWHM at m/z 400. The maximum injection time was set to 100 ms with one micro scan 176 
for MS mode and to 500 ms with one micro scan for MSn mode. TPs were fragmented in 177 
the HCD Collision Cell because some metabolites were not fragmented in the trap. The 178 
selected HCD voltage was 45 V, although in some cases it was raised to 50 and 60 V. The 179 
mass range was from m/z 100 to 1000.  180 
 181 
2.4. Procedures 182 
2.4.1 Thermal study 183 
In this study, individual standards of quinolones (ENR, CIP, DIF and SAR) at 1 µg·mL-1 in 184 
water were warmed to degrade the antibiotics. All quinolones were heat-treated under 185 
conditions of temperature and time corresponding to three thermal processes of milk: 186 
pasteurization at 60ºC for 30 min (T1) or 72ºC for 15 s (T2) and sterilization at 120ºC for 187 
20 min (T3). Subsequently, individual milk samples spiked with ENR, CIP, DIF and SAR 188 
were warmed at 120ºC for 20 and 60 min (T3.20 and T3.60). The samples heated at 189 
different temperatures were compared with spiked non-heated samples (T0) and with blank 190 
milk samples at same thermal condition, ie, for example samples at T3.20 were compared 191 
with blank at T3.20. Milk samples from animals medicated with ENR were also thermally 192 
treated at T3.20 and T3.60 and compared with the same sample but non-heated. All 193 
experiments were made by triplicate. 194 
 195 
2.4.2. Sample treatment and clean-up (SPE) 196 
The method for analyzing the milk sample was used previously to determine the antibiotics 197 
in the milk9-12. The extraction method consist of the addition of 0.5 mL of phosphate 198 
solution 0.1 M at pH 10 and 2 mL of water to 2 g of milk, centrifugation of samples, and an 199 
SPE process. The SPE cartridges used were Oasis HLB and these were preconditioned 200 
with 1 mL of MeOH, 1 mL of water and 1 mL of 0.1 M phosphate solution at pH 10. After 201 
sample loading, the cartridge was washed with 3 mL of water and the analytes were eluted 202 
with 2 mL of MeOH. 203 
 204 
The methanolic fraction eluted from the SPE was evaporated to dryness under a nitrogen 205 
stream by TurboVap LV and a water temperature of 35ºC. The extract was then 206 
reconstituted with 200 µL of water and filtered through membrane filters (Ultra free 207 
Durapore PVDF 0.22 µm from Millipore), before injection into the LC-LTQ-Orbitrap. 208 
 209 
2.4.2. Data treatment  210 
The LC-ToF data were treated using two procedures to find metabolites and TPs in milk 211 
samples from medicated cow with ENR. The first corresponds to the manual comparison 212 
of mass spectra of blanks and samples. This procedure was used initially to detect the TPs 213 
in standards and spiked cow milk. The other option consists of the use of Mzmine242,43 free 214 
software, which provides a list of all m/z on mass spectra. The list can be shortened by 215 
removing all the ions that only appear in the blank spectra and those that have a similar or 216 
higher intensity in the blanks than in the samples. Only the ions which appeared between 1 217 
to 9 min and from 150 to 800 Da were considered. Also, a mass defect filter (MDF) of 120 218 
mDa was applied. 219 
 220 
 221 
3. RESULTS AND DISCUSSION 222 
3.1. Determination of thermal TPs by LC-ToF-MS 223 
Blank and spiked water samples were subjected to the thermal conditions explained in 224 
Section 2.3.1 and analysed by LC-ToF-MS. The total ion current chromatograms (TIC) of 225 
spiked water samples were compared with the TIC of blank water samples to examine for 226 
possible TPs. The two chromatograms were nearly identical, except for the spiked 227 
antibiotic peak. 228 
 229 
The mass spectra of blank and spiked water samples were compared by overlapping. The 230 
only difference between the spiked sample and the blanks was the peak of parent 231 
compound. However, a decrease in the area of the protonated molecule of quinolones was 232 
noticed when the temperature rose. The highest decrease was seen when the samples were 233 
heated at 120ºC for 20 min (T3.20) where in some cases up to 20%. A new condition of 234 
120ºC for 60 min (T3.60) was also applied to ensure that TPs were obtained in sufficient 235 
high concentrations to be detected. 236 
 237 
Raw cow milk samples free of quinolones were spiked and heated under the selected 238 
conditions. To assess whether any TPs had formed, the same procedure as that used for the 239 
water standards was followed. In this case, some ions were identified in the mass spectra of 240 
the spiked milk samples that were not observed in the blank milk samples. Some ions were 241 
identified as doubly charged protonated molecules, with characteristic losses of water and 242 
carbon dioxide. These ions were also detected in the water samples. The doubly protonated 243 
identity was confirmed by the isotopic pattern. The difference between [M+2H]2+ and 244 
[M+1+2H]2+ was m/z 0.5. In addition, the same retention time (tR) of the compounds in the 245 
extracted ion chromatogram (EIC) was observed44. The losses of H2O (18.0105) and CO2 246 
(43.9898) are not considered as TPs because these were also observed in the source by 247 
CID-in-source fragmentation40,45-48. The ions m/z 332.1405 and 386.1311 were detected in 248 
samples that were spiked with ENR and DIF respectively. These m/z values are consistent 249 
with the m/z of CIP and SAR. The EIC were obtained for blank and spiked samples to 250 
check the presence of TPs. Table 1 shows all the ions found in milk and their 251 
identification, sorted by the original antibiotic. As can be observed, the errors between 252 
experimental mass and assigned structure were lower than 3.0 ppm. 253 
 254 
To assign a structure to the remaining of the ions that were observed, an in-house database 255 
was created using a list of 106 metabolic reactions49 that can take place in milk, and 256 
another list of milk components (including carbohydrates, amino acids, vitamins and lipids; 257 
a total of 188 components)50. The exact mass of the starting antibiotic or a known fragment 258 
is introduced into the database and a series of combinations of reactions and/or possible 259 
additions are obtained that give rise to a molecule with an exact mass similar to that 260 
observed in the mass spectra of ToF. 261 
 262 
 263 
3.2. Identification of thermal TPs by LC-LTQ-Orbitrap-MS 264 
As a ToF spectrometer cannot fragment molecules, we used an LTQ-Orbitrap to elucidate 265 
the TPs, as it has a higher mass resolving power than ToF and can fragment the compound 266 
to obtain structural information. 267 
 268 
For each quinolone, Table 2 shows the retention time (tR), m/z values, the gains and losses 269 
of mass compared to the parent quinolone, the m/z of the TPs observed, and the fragments 270 
observed in mass spectra. Table 2 also shows the proposed reactions, with the assigned 271 
molecular formula, the double bond equivalents (DBE) of neutral molecules, the 272 
theoretical mass, and the error in ppm calculated for the formula. The information is 273 
provided as common reactions that occurred in all the studied quinolones, and other 274 
reactions that were only observed in some quinolones. 275 
 276 
Common reactions of the four quinolones 277 
 278 
Several gains and losses of mass were common among the four quinolones studied. Our 279 
database shows that the gain of 15.9949 m/z (Table 2) could correspond to two different 280 
reactions: hydroxylation and N-oxide formation. An evaluation of MS/MS spectra could be 281 
used to differentiate between both structures. As an example, Figure 2A shows the MS/MS 282 
spectrum of ions m/z 416.1416 in samples of DIF and discussion about elucidation is given 283 
in supporting information. The position of OH could not be assigned with certainty, but our 284 
proposal is hydroxylation in position 3 of the piperazine ring, as in oxo-ciprofloxacin, the 285 
metabolite described in the bibliography36,37,40. For the four quinolones, the hydroxylated-286 
TPs were observed, but the concentration of TPs from ENR and DIF were higher than CIP 287 
and SAR ones.  N-oxide formation only occurred in ENR and DIF in N4-alkylpiperazinyl. 288 
This metabolite has been described previously38,51. For this structure, a loss of OH is 289 
characteristic in fragmentation and was experimentally observed in Figure 2B of the 290 
MS/MS spectrum of ions m/z 416.1416 for DIF. In this case, the DBEs of TPs undergo no 291 
alteration of values in comparison to the DBE of parent quinolones. Different 292 
fragmentation patterns were observed for the hydroxylated and N-oxide compounds that 293 
were found, as can be observed in Figure 2A and B. In Figure 2B, corresponding to the N-294 
oxide TP, the peak of the precursor ion disappeared almost completely when the same 295 
voltage was applied (HCD: 45). This finding suggests that hydroxylated compounds are 296 
more stable than N-Oxide TP. The structures assigned to the rest of the ions are shown in 297 
Figure 2. Table 2 shows the fragmentation ions, the molecular formula, the DBE, and the 298 
calculated error in the assignation of the different structures. 299 
 300 
A gain of 29.9740 m/z was also observed for the four quinolones, as shown in Table 2. 301 
Three peaks were found for ENR and DIF, whereas only one peak was observed for their 302 
main metabolites (CIP and SAR), at a concentration too low to be isolated and fragmented. 303 
The mass spectra of all peaks of ENR and DIF were studied. Figure 3 shows the mass 304 
spectra of ions with m/z 390.1460 of ENR. In Figure 3A, the separation by LC-LTQ-305 
Orbitrap is shown with peaks at 5.71, 7.57 and 7.99 min. Although the retention time of 306 
ENR matches peak 1, the mass spectra are different, as can be observed in Figures 3B and 307 
C. A comparison of both mass spectra revealed only two ions (m/z 245.1077 and 72.0805) 308 
in common. The m/z 245.1077 indicates that the differences between the TP of peak 1 and 309 
ENR are in the loss fragment (part of the piperazinyl ring). The accurate mass of the 310 
fragment m/z 128.0706 corresponds to molecular formula C6H10NO2 with a DBE value of 311 
3 and is the key to the elucidation as is shown in Figure 3C and in the supporting 312 
information52. 313 
 314 
Unlike the first molecule, the other two ions of m/z 390.1460 (peaks 2 and 3) had low 315 
fragmentation as can be observed in Figure 3. Nevertheless, their structures were 316 
elucidated. The retention time of these peaks are different, but their mass spectra are 317 
identical, which indicates that they are isomers (Figure 3D). The m/z 245.1085 observed in 318 
the mass spectrum of ENR (Figure 3B) could not be found in the spectra of peaks 2 and 3. 319 
The molecules were broken up from the piperazinyl ring, resulting in the ions 100.0756 320 
and 291.0774. The fragment 100.0756 is the same as that observed in Figure 3C, which 321 
indicates that there was only a ketone in the ring. The fragmentation of 291.0774 makes us 322 
to conclude that OH is on the aromatic ring. Two different vacant positions in the aromatic 323 
ring led to the two different isomers. For DIF, the fragmentations were similar to those 324 
shown in ENR, as can be observed in Table 2.  325 
 326 
TPs corresponding to net loss of 26.0146 were observed for all compounds (ENR, CIP, 327 
DIF and SAR). For the TPs of ENR and DIF the losses of N4-alkylamine from piperazinyl 328 
ring were observed. However, as CIP and SAR do not have an alkyl group in N4, the losses 329 
of ammonia (17.0275) were seen.  Moreover, the TPs had DBE one unit lower than the 330 
parent compound, due to the break in the piperazinyl ring. Therefore, the peaks at m/z 331 
334.1560, 306.1246, 374.1307 and 360.1156 have been assigned to desethylenequinolone 332 
TPs34-37. As Table 2 shows, when Orbitrap was used to elucidate the structures, the 333 
calculation errors (ppm) were lower than 2 ppm. Slightly higher error values were obtained 334 
when ToF was used. 335 
 336 
Other reactions 337 
The major metabolites, CIP and SAR, underwent other transformations, as can be observed 338 
in Table 2. Due to the absence of the alkyl chain in the N4-piperazinyl ring, two reactions 339 
acetylation (Acetyl-CIP (m/z 374.1509) and Acetyl-SAR (m/z 428.1416)) and 340 
formamidation (Formamide-CIP (m/z 375.1463) and Formamide-SAR (m/z 429.1416)) 341 
took place. The corresponding explanation of elucidation is in supplementary material. 342 
 343 
In addition to the above-mentioned reactions, CIP gave three more TPs (m/z: 274.0986, 344 
573.1429 and 656.2457). The ion 573.1429 was observed at a very low concentration and 345 
could not be fragmented. For the mass 274.0986, the ion 292.1091 could also be observed, 346 
at less intensity, corresponding to the gain of a water molecule. The main ion obtained by 347 
MS2 of the ion 274.0986 was 231.0564, and this was isolated and fragmented again. In the 348 
MS3 spectrum, the ion m/z 249.0668 was also observed with m/z 231.0564 which 349 
corresponds to gain of a water molecule. This gain of water was only observed in the ions 350 
that kept the carbonyl group of acid, which is capable of hydrating the initial carboxylic 351 
acid again. The rest of the ions were mainly due to fragmentation of the piperazine ring. 352 
The structure assigned to m/z 292.1091 was CIP, with loss of the cyclopropyl group. 353 
 354 
The last TP (656.2457) was obtained by heating the spiked milk sample with CIP at T3.60.  355 
When a HCD voltage of 45 V was used, only fragments with low m/z were found. To 356 
obtain structural information, the voltage was reduced to 35 V. The CIP ion (m/z 332.1400) 357 
could be identified among all the fragments as can be seen in Figure 4. As can be followed 358 
in supporting information, the molecule CIP (332.1405) is combined with the lactose 359 
(galactose + glucose) present in milk at high concentration. This new product was favoured 360 
when samples were heated at a high temperature for a long time (60 min). 361 
 362 
3.3. Effect of temperature on the stability of TPs 363 
For each TP ion, the areas obtained from milk samples were plotted vs. the heating 364 
conditions (T0, T3.20 and T3.60) (Figure 5). For ENR and CIP (Figure 5A and 5B), all the 365 
TPs were observed at T0 except for hydroxylated quinolones (m/z 376.1656_1 and 366 
348.1334, respectively). The concentration of these ions was raised by heating at T3.20, 367 
and disappeared at T3.60. In the case of ENR (Figure 5A), the concentration of some TPs, 368 
including CIP (332.1402), desethylene-ENR (334.1569) and two isomers of hydroxylation 369 
and ketone formation (390.1461_1 and 390.1461_3), increased slightly by warming at 370 
T3.20, and decreased at T3.60. For CIP, T3.60 was required for conjugation with lactose 371 
(656.2477) to occur (Figure 5B). The acetylated (374.1535) and formamidated (375.1463) 372 
were present at T0 and their concentrations increased by heating. The 362.1148 ion 373 
(corresponding to gain [M+H+29.974]+) was initially present (T0), but was destroyed by 374 
heating. 375 
 376 
In contrast, the concentration of most of the ions in DIF samples increased slightly when 377 
the temperature was increased (Figure 5C). A general downward trend of DIF ions was 378 
seen at T3.60. Completely different behaviour was observed for the 430.1185_3 ion, which 379 
underwent sharp decrease at T3.20 and a sharp rise in formation when the warming time 380 
was increased, possibly due to the ion coming from different sources, and for the 381 
430.1185_1 ion, which disappeared completely at T3.20. The acetylated (428.1407) and 382 
formamidated (429.1391) TPs of SAR (Figure 5D) behaved in the same way as those of 383 
CIP, i.e., their concentration increased with temperature.  384 
 385 
3.4 Determination of metabolites and TPs in medicated cow milk 386 
Four raw milk samples from cows medicated with ENR were submitted to the same 387 
thermal treatments as the spiked milk samples. The extracts were analysed by LC-ToF and 388 
the metabolites and TPs were fragmented by LC-LTQ-Orbitrap. 389 
 390 
In this case, metabolites and TPs were found using the two data treatments (Section 2.3.3). 391 
When exact mass, retention time and MS/MS spectra were compared, some of the 392 
compounds in milk spiked with ENR and CIP were also present in medicated cow milk.  393 
 394 
Table 3 shows the retention time (tR) of metabolites in samples analysed by LC-ToF, the 395 
accurate m/z of metabolites determined by ToF and LTQ-Orbitrap, the assigned molecular 396 
formula, the theoretical mass, the error in ppm calculated for the assigned formula, the 397 
proposed structures, and the double bond equivalents (DBE) of the neutral molecule. 398 
 399 
CIP (m/z 332.1405), the main metabolite of ENR, was one of the common compounds. In 400 
addition, desethylene metabolites of ENR (m/z 334.1561)(ENR-6) and CIP (m/z 401 
306.1248)(ENR-3) were observed. The TPs of ENR corresponded to hydroxylation (ENR-402 
16) and N-Oxide formation (ENR-17)(m/z 376.1667) and two isomers of compound m/z 403 
390.1460 (ENR-18 and ENR-19) (hydroxylation and ketone formation, Figure 3D) were 404 
also found. Four TPs of CIP were observed in medicated cow milk. At 3.6 min was found 405 
the hydroxy-CIP (m/z 348.1354)(ENR-8) and at 6.1 min the m/z 362.1147(ENR-11), 406 
although this time the MS2 spectrum could not be obtained due to its low concentration. 407 
The other metabolites were from acetylation (m/z 374.1511)(ENR-14) and formamidation 408 
(m/z 375.1463)(ENR-15) of CIP. 409 
 410 
Other compounds were found in milk from medicated cows, but not in spiked milk. These 411 
compounds were produced by metabolism of the antibiotic in the cow, and some of them 412 
were identified for the first time.  413 
 414 
The metabolite with the highest intensity after CIP (332.1405) and desethylene-ENR 415 
(334.1561)(ENR-6) had m/z 263.0834 (ENR-1). The m/z of the metabolite was lower than 416 
the m/z of ENR. Therefore, the MS/MS spectrum was analysed to find which part of the 417 
parent compound had been modified. Figure 6A shows MS/MS spectrum of ENR-1.  It 418 
was concluded that the metabolite structure corresponded to CIP without a piperazine ring 419 
(Supporting information). Only the amino group was maintained, as shown in Table 3. 420 
 421 
In the MS/MS spectrum of metabolite ENR-2 with m/z 291.0783 (Figure 6B), the ion m/z 422 
263.0834 (ENR-1), discussed above in supporting information and in Figure 6A, was 423 
observed. The difference between both ions corresponded to a carbonyl group (27.9949). 424 
The assigned structure for this metabolite is given in Table 3. 425 
 426 
Another metabolite elucidated was m/z 307.1095 (ENR-4). Some explanations of the 427 
fragments are shown in Figure 6C and supporting information. Its structure can be 428 
observed in Table 3. 429 
 430 
The ion m/z 334.1189 (ENR-5) was identified as formyldesethylene-CIP25. Its structure 431 
was checked by its mass spectrum. The molecule was broken up from the piperazinyl ring, 432 
resulting in the ions m/z 72.0445 and 263.0834 cited before. Other important fragments 433 
were m/z 245.0730 [263.0834-H2O], 230.0489 [334.1189-H2O-Cyclopropyl-Formamide] 434 
and 217.0411 [230.0489-CH]. 435 
 436 
A compound (ENR-9) with the same m/z as hydroxy-CIP (m/z 348.1354)(ENR-8) was also 437 
studied, because the retention time differed by about 4 minutes from the peak observed in 438 
spiked samples. The MS/MS spectrum (Figure 6D) was very similar to the spectrum of 439 
formyldesethylene-CIP (m/z 334.1189)(ENR-5). The most striking difference between both 440 
spectra was that instead of fragment m/z 72.0444 was observed a fragment of m/z 86.0601. 441 
This fragment corresponds to the addition of a methyl group to fragment m/z 72.0444. In 442 
conclusion, a structure of acetyldesethylene-CIP (ENR-9) is suggested, which could be 443 
formed from the oxidation of the side chain of desethylene-ENR (m/z 334.1561)(ENR-6). 444 
 445 
The EIC of ion m/z 362.1137 (ENR-12 and ENR-13) from a full-scan of ToF was very 446 
similar to that obtained for the m/z 390.1460 (ENR-18 and ENR-19) in spiked samples 447 
with ENR (Figure 3). Three peaks were observed in the EIC. The first one was at 6.1 min, 448 
which coincides with the peak observed in samples fortified with CIP. Also were seen two 449 
peaks at 6.8 and 7.1 min, with the same shape as the two peaks at 7.6 and 7.99 in Figure 3. 450 
Unfortunately, when the sample was analysed by LC-LTQ-Orbitrap, it was degraded and 451 
only one peak was observed and fragmented. In the MS/MS spectrum, the ions m/z 452 
291.0776 and 259.0820 were present, as elucidated previously in Figure 3D. Another 453 
fragment that helped to determine the structure corresponded to m/z 72.0444, which is like 454 
fragment 100.0757 of metabolite 390.1460 without the alkyl chain of ENR. Due to the 455 
resemblances between the EICs and mass spectra of ions m/z 362.1137 (ENR-12 and ENR-456 
13) and 390.1460 (ENR-18 and ENR-19), can be assume that these compounds are the 457 
same, but one is from CIP and the other from ENR, respectively. 458 
 459 
The last two elucidated metabolites corresponded to oxo-CIP (m/z 346.1198)(ENR-7) and 460 
formyl-CIP (360.1354)(ENR-10), which have been described previously in literature36,40. 461 
Their structures were confirmed by their MS/MS spectra. 462 
 463 
The rest of the metabolites found in medicated cow milk could not be elucidated. In any 464 
case, Table 3 shows their m/z, retention time (tR), hypothetical molecular formula, double 465 
bond equivalents (DBE) and errors in ppm. 466 
467 
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FIGURE CAPTIONS 638 
 639 
Fig 1 640 
Structures of the four quinolones studied (ENR, CIP, DIF and SAR).  641 
 642 
Fig 2 643 
A) MS2 spectrum for the hydroxylated TP of DIF. B) MS2 spectrum for the N-oxide TP of 644 
DIF. 645 
 646 
Fig 3 647 
A) EIC of ion m/z 390.1460 in the milk sample spiked with ENR. B) MS2 spectrum for 648 
ENR. C) MS2 spectrum for the first peak (tR 5.71 min). D) MS2 spectrum for the remaining 649 
peaks (tR 7.57 and 7.99 min). 650 
 651 
Fig 4 652 
Product ion scan (MS2) of CIP lactose conjugate (precursor ion m/z 656.2457). Top left, 653 
extended mass spectrum where losses of water molecules are shown. 654 
 655 
Fig 5 656 
Influence of the different warming conditions in areas of different TPs of ENR, CIP, DIF 657 
and SAR. 658 
 659 
Fig 6 660 
MS2 spectra for the metabolites of ENR. A) m/z 263.0828 (ENR-1). B) m/z 291.0776 661 
(ENR-2). C) m/z 307.1089 (ENR-4). D) m/z 348.1354 (ENR-9). 662 
663 
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Section 3.2: Common reactions of the four quinolones 
 
1. TPs of DIF (m/z 416.1416) 
In the mass spectrum of the ion m/z 416.1416 (Figure 2A), two losses of water (18.0105 
m/z) were observed. The first was due to carboxylic acid and the same loss was 
observed for the rest of the quinolones. The second loss of water observed in the spectra 
is only possible if an OH group is in position 2 or 3 of the piperazine ring. 
 
2. TPs of ENR (m/z 390.1460) Peak 1 
The accurate mass of the fragment m/z 128.0706 corresponds to molecular formula 
C6H10NO2 with a DBE value of 3 and is the key to the elucidation (Figure 3C). This was 
followed by two consecutive fragmentations, corresponding to losses of 27.9949 (CO) 
[128.0706 - CO → 100.0756; 100.0756 - CO → 72.0808] and the reduction of one unit 
of DBE. These fragments indicate that a ketone and an alcohol are present in the 
piperazinyl ring, as observed in the suggested fragmentation shown in Figure 3C. The 
rest of the fragments are due to losses of CO2, H2O and pieces of the piperazine ring. It 
should be noted that the DBE of some fragments such as m/z 301.0982 and 328.1454 
are 10.5. The structures represented in the mass spectrum (Figure 3C) have 11 
unsaturations (double bonds and rings). The DBE calculated is the average of the 
resonance structures of drawn structure (DBE: 11) and the carbocation (DBE:10)52. 
 
 
Section 3.2: Other reactions  
1. TPs of CIP and SAR (acetylation and formamidation) 
Two different reactions took place on CIP and SAR. The first was acetylation, which 
could be justified by a loss of acetyl group (42.0103) (Acetyl-CIP(-H2O): 356.1402 → 
314.1297 and Acetyl-SAR(-H2O): 410.1310 → 368.1203), as observed in the MS 
spectra (not shown). The second reaction corresponds to formamidation. For CIP and 
SAR, the loss of formamide and subsequent gain of 2H occurred in one step 
(Formamide-CIP(-H2O): 357.1356 → 314.1296 and Formamide-SAR(-H2O): 411.1264 
→ 368.1205). Moreover, in the case of CIP, the loss of NH3 (357.1356 → 340.1096), 
followed by the loss of a carbonyl and gain of 2H (340.1096 → 314.1296), were also 
observed. Due to the absence of the alkyl chain in the N4-piperazinyl ring, both 
reactions (acetylation and formamidation) took place. 
2.  TPs of CIP (m/z 656.2457)  
Figure 4 shows the mass spectrum of this TP with its fragmentations. The two main 
characteristic losses were the loss of -180.0633 (656.2457 → 476.1825), which 
corresponds to the loss of a glucose, and the loss of a galactose without a water 
molecule (476.1825 → 344.1400). In the spectrum, steady losses of six water molecules 
were observed due to the OH present on the sugars, as can be seen in the smaller mass 
spectrum in Figure 4. All these losses could be explained if the molecule CIP 
(332.1405) is combined with the lactose (galactose + glucose) present in milk at high 
concentration. This new product was favoured when samples were heated at a high 
temperature for a long time (60 min). 
 
Section 3.4: Determination of metabolites and TPs in medicated cow milk  
1. Metabolite ENR-1 (m/z 263.0834) 
In the MS/MS spectrum of ENR-1 (Figure 6A), the loss of a water molecule (263.0834 
→ 245.0729) and CO (245.0729 → 217.0778) from carboxylic acid can be observed. 
The presence of cyclopropyl can also be justified by ion m/z 222.0441, which is the 
result of the loss of cyclopropyl from the parent metabolite (263.0834 – 41.0391 → 
222.0441). 
2. Metabolite ENR-4 (m/z 307.1095) 
In this case, characteristic losses of the carboxylic group and cyclopropyl could be 
observed in the spectrum of ENR-4 (Figure 6C). The modifications of structure with 
respect to ENR, were again found over the piperazine ring. As can be seen, the ion m/z 
248.0596 loses the methyl group, which results in the ion m/z 235.0520 that later loses a 
molecule of water (235.0520 → 217.0411). 
 
 
